Phase I results for Imutex’s mosquito vaccine candidate published in leading peer-reviewed journal
Poolbeg Pharma PLC (AIM:POLB) POLB 001 LPS human challenge trial completed
POLB 001 LPS human challenge clinical trial successfully completed
Ex-boyfriend of Elizabeth Holmes sentenced to almost 13 years imprisonment for Theranos fraud
Judge sentences Elizabeth Holmes, a former aide to the founder of Theranos, to 15 years in prison for convincing people to trust her failed blood-testing startup.
ValiRx PLC (AIM:VAL) Quarterly Operational and Strategy Update
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.
Novacyt S.A. (AIM:NCYT) Approval of genesig COVID-19 3G PCR test in UK
Approval of genesig® COVID-19 3G PCR test in the UK under CTDA legislation
OKYO Pharma LTD (AIM:OKYO) publicly files a registration statement with the SEC
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease
Poolbeg Pharma PLC (AIM:POLB) Influenza Artificial Intelligence model build completed
CytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023
Abingdon Health PLC (AIM:ABDX) Preliminary Results
York, U.K. 24 November 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces its preliminary results for the year ended
Deepverge PLC (AIM:DVRG) Accelerated Restructuring
DeepVerge (AIM: DVRG) announces an organisational restructure of its environmental and life science divisions to meet the growth in demand and maximise the opportunities that lie ahead.
OKYO Pharma LTD (AIM:OKYO) Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-
Disgraced Theranos founder Elizabeth Holmes has been sentenced to more than 11 years in prison for fraud
Federal Judge Elizabeth Holmes, the founder of Theranos, sentenced her Friday to 11 years and 3 months imprisonment for defrauding investors in her now-defunct startup blood-testing that was once valued